Second Sight Medical Products Inc. [NASDAQ: EYES] price surged by 27.43 percent to reach at $2.03. The company report on April 6, 2021 that Second Sight Medical Products Names Dean Baker and Alexandra Larson to its Board of Directors.
Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced that the Company’s Board of Directors has appointed two new members, Dr. Dean Baker and Ms. Alexandra Larson. Dr. Baker has also been appointed to the Audit Committee of the Board.
“We are honored and excited to add these two very talented individuals to our board,” said Gregg Williams, Chairman of the Board. “I have worked with both for many years and know they are the exact blend of talent and experience we need to move this company strongly forward in our mission to cure all forms of blindness,” concluded Williams.
A sum of 53702326 shares traded at recent session while its average daily volume was at 23.93M shares. Second Sight Medical Products Inc. shares reached a high of $10.67 and dropped to a low of $7.40 until finishing in the latest session at $9.43.
Guru’s Opinion on Second Sight Medical Products Inc. [EYES]:
Dougherty & Company have made an estimate for Second Sight Medical Products Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 13, 2019. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on July 06, 2015, representing the official price target for Second Sight Medical Products Inc. stock.
The Average True Range (ATR) for Second Sight Medical Products Inc. is set at 2.25
EYES Stock Performance Analysis:
Second Sight Medical Products Inc. [EYES] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.86. With this latest performance, EYES shares gained by 62.87% in over the last four-week period, additionally plugging by 955.16% over the last 6 months – not to mention a rise of 1022.62% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EYES stock in for the last two-week period is set at 53.16, with the RSI for the last a single of trading hit 51.63, and the three-weeks RSI is set at 54.77 for Second Sight Medical Products Inc. [EYES]. The present Moving Average for the last 50 days of trading for this stock 6.05, while it was recorded at 8.19 for the last single week of trading, and 2.34 for the last 200 days.
Insight into Second Sight Medical Products Inc. Fundamentals:
Return on Total Capital for EYES is now -222.13, given the latest momentum, and Return on Invested Capital for the company is -331.85. Return on Equity for this stock declined to -450.70, with Return on Assets sitting at -141.32. Additionally, EYES Total Debt to Total Capital is recorded at 143.98, with Total Debt to Total Assets ending up at 49.33.
Reflecting on the efficiency of the workforce at the company, Second Sight Medical Products Inc. [EYES] managed to generate an average of -$1,240,000 per employee.Second Sight Medical Products Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.80 and a Current Ratio set at 0.80.
EYES Stock EPS
With the latest financial reports released by the company, Second Sight Medical Products Inc. posted -0.48/share EPS, while the average EPS was predicted by analysts to be reported at -0.48/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EYES.
Second Sight Medical Products Inc. [EYES] Insider Position Details
There are presently around $5 million, or 3.00% of EYES stock, in the hands of institutional investors. The top three institutional holders of EYES stocks are: VANGUARD GROUP INC with ownership of 405,702, which is approximately 210.483% of the company’s market cap and around 42.84% of the total institutional ownership; GEODE CAPITAL MANAGEMENT, LLC, holding 72,244 shares of the stock with an approximate value of $0.54 million in EYES stocks shares; and TOWER RESEARCH CAPITAL LLC (TRC), currently with $0.29 million in EYES stock with ownership of nearly New of the company’s market capitalization.
Positions in Second Sight Medical Products Inc. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 14 institutional holders increased their position in Second Sight Medical Products Inc. [NASDAQ:EYES] by around 434,804 shares. Additionally, 8 investors decreased positions by around 690,108 shares, while 4 investors held positions by with 439,940 shares. The mentioned changes placed institutional holdings at 684,972 shares, according to the latest SEC report filing. EYES stock had 7 new institutional investments in for a total of 114,403 shares, while 6 institutional investors sold positions of 595,791 shares during the same period.